Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.42 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13482020 | 0.89 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10CHRM5CHRM1 | |
| SCHEMBL2706963 | 0.88 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10CHRM5CHRM1 | |
| SCHEMBL10458715 | 0.87 | ALOX15 (0.46) | ALDH1A1LMNAHSD17B10CHRM5CHRM1 | |
| SCHEMBL713608 | 0.85 | — | — | |
| SCHEMBL12814201 | 0.85 | — | — | |
| SCHEMBL197897 | 0.85 | — | — | |
| SCHEMBL6572365 | 0.85 | — | — | |
| SCHEMBL21715100 | 0.83 | — | — | |
| SCHEMBL5171320 | 0.83 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10CHRM5CHRM1 | |
| SCHEMBL30662414 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327458-A1 | MACROCYCLIC PEPTIDOMIMETIC PROTEASE INHIBITOR AND USE THEREOF | TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITED (CN) | 2024-10-03 | — | — | US | claimed |
| EP-4406962-A1 | MACROCYCLIC PEPTIDOMIMETIC PROTEASE INHIBITOR AND USE THEREOF | Tencent Technology (Shenzhen) Company Limited (CN) | 2024-07-31 | — | — | EP | claimed |
| EP-1851322-B1 | METHOD FOR THE ENANTIOSELECTIVE ENZYMATIC REDUCTION OF KETO COMPOUNDS | IEP GMBH (DE) | 2009-10-21 | — | — | EP | claimed |
| EP-1714977-B1 | Synthesis of cyclosporin analogs | ISOTECHNIKA INC (CA) | 2009-03-11 | — | — | EP | claimed |
| EP-1714977-A2 | Synthesis of cyclosporin analogs | Isotechnika Inc. (CA) | 2006-10-25 | — | — | EP | claimed |
| EP-1436321-A2 | SYNTHESIS OF CYCLOSPORIN ANALOGS | Isotechnika Inc. (CA) | 2004-07-14 | — | — | EP | claimed |
| US-20030212249-A1 | Synthesis of cyclosporin analogs | ISOTECHNIKA, INC. (CA) | 2003-11-13 | — | — | US | claimed |
| WO-2003033526-A2 | SYNTHESIS OF CYCLOSPORIN ANALOGS | ISOTECHNIKA INC. (CA) | 2003-04-24 | — | — | WO | claimed |
| JP-9278726-A | — | — | None | — | — | JP | disclosed |
| EP-4731623-A1 | CARBOLINE COMPOUNDS AND USE THEREOF | PTC Therapeutics, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2025006078-A1 | CARBOLINE COMPOUNDS AND USE THEREOF | PTC THERAPEUTICS, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20240327458-A1 | MACROCYCLIC PEPTIDOMIMETIC PROTEASE INHIBITOR AND USE THEREOF | TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITED (CN) | 2024-10-03 | — | — | US | disclosed |
| US-20240301460-A1 | ENZYMATIC SYNTHESIS OF 4'-ETHYNYL NUCLEOSIDE ANALOGS | MERCK SHARP & DOHME LLC (US) | 2024-09-12 | — | — | US | disclosed |
| EP-4406962-A1 | MACROCYCLIC PEPTIDOMIMETIC PROTEASE INHIBITOR AND USE THEREOF | Tencent Technology (Shenzhen) Company Limited (CN) | 2024-07-31 | — | — | EP | disclosed |
| US-5530140-A | Free radicals | NYCOMED IMAGING AS (NO) | 1996-06-25 | — | — | US | disclosed |
| EP-0704419-A1 | PROCESS FOR PRODUCING TRIAZOLE DERIVATIVE | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1996-04-03 | — | — | EP | disclosed |
| EP-0272671-B1 | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors | SANDOZ LTD (CH) | 1994-03-16 | — | — | EP | disclosed |
| US-5158936-A | Treating or prevention of tissue damage, inflammation, bone resporpption and muscular dystrophy | SYNTEX (U.S.A.) INC. (US) | 1992-10-27 | — | — | US | disclosed |
| US-5055451-A | Prevent tissue damage | SYNTEX INC. (US) | 1991-10-08 | — | — | US | disclosed |
| EP-0272671-A2 | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors | SANDOZ LTD. (CH) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327458-A1 | MACROCYCLIC PEPTIDOMIMETIC PROTEASE INHIBITOR AND USE THEREOF | ACE, FURIN, ACE2 | ALDH1A1 4138/4885LMNA 2819/4885HSD17B10 1656/4885 |
| US-20240301460-A1 | ENZYMATIC SYNTHESIS OF 4'-ETHYNYL NUCLEOSIDE ANALOGS | GALE, ENGASE, RNGTT | ALDH1A1 464/4885LMNA 2520/4885HSD17B10 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.